JP3308433B2 - Skin activating food - Google Patents
Skin activating foodInfo
- Publication number
- JP3308433B2 JP3308433B2 JP24863195A JP24863195A JP3308433B2 JP 3308433 B2 JP3308433 B2 JP 3308433B2 JP 24863195 A JP24863195 A JP 24863195A JP 24863195 A JP24863195 A JP 24863195A JP 3308433 B2 JP3308433 B2 JP 3308433B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- group
- extract
- ginseng
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、杜仲若しくはその
抽出物及び人参若しくはその抽出物及びコラーゲン若し
くはその抽出物を必須成分とする皮膚賦活食品、さらに
詳しくは、生体の新陳代謝を促進し、特に皮膚のターン
オーバーを改善する皮膚賦活食品に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to eucommia or its extract and carrot or its extract and collagen
Clause skin activation food you the extract as an essential component, and more particularly, to promote the metabolism of the body, especially on the skin activation food you improve the turnover of skin.
【０００２】[0002]
【従来の技術】通常若い肌は、新陳代謝を活発に行い、
疲労、機能低下等を素早く改善する。しかしながら、加
齢変化に伴い、組織の新陳代謝は低下し、特に、皮膚の
ターンオーバー期間が長くなり、組織疲労と萎縮、酸化
が進むことにより本来の機能が低下する現象が観察され
ている。この新陳代謝の低下により健康が害されるおそ
れがあり、各種疾病にかかりやすく、また疾病からの回
復を遅らせてしまう。さらに、新陳代謝の低下により肌
のハリの低下、小ジワ、くすみ等の問題を生じる。そこ
で、この新陳代謝の低下を改善する対応策が考慮されて
いる。2. Description of the Related Art Normally, young skin actively metabolizes,
Improve fatigue and functional deterioration quickly. However, with the aging change, the metabolism of the tissues has been reduced, and in particular, a phenomenon has been observed in which the turnover period of the skin is prolonged and the original functions are reduced due to the progress of tissue fatigue, atrophy and oxidation. This decrease in metabolism may impair health, easily cause various diseases, and delay recovery from the diseases. Further, a decrease in metabolism causes problems such as a decrease in skin firmness, fine wrinkles and dullness. Therefore, countermeasures for improving this decrease in metabolism are being considered.
【０００３】これを改善するため現在上市されている商
品の一つに、コラーゲンと杜仲葉とＤＮＡ核酸とカルシ
ウムと各種ビタミンを配合したものがある。また、これ
にさらにフラクトオリゴ糖を加えたものもある。これら
を食生活中に取り入れることにより新陳代謝を促進する
というものである。また、新陳代謝を促進する組成物に
関し、特開平１−１０８９６３号公報で開示されたもの
がある。これは、朝鮮人参と杜仲葉若しくはそれらの抽
出物からになり、これを飲用することにより新陳代謝が
促進されるというものである。しかしながら、この組成
物においては、朝鮮人参の配合により尿の出が悪くなる
という欠点が報告されている。[0003] To improve this, one of the products currently on the market is a product containing a combination of collagen, Tonaka leaf, DNA nucleic acid, calcium and various vitamins. In addition, there are also those in which fructooligosaccharides are further added. The metabolism is promoted by incorporating them into the diet. Further, a composition for promoting metabolism is disclosed in JP-A-1-1088963. It consists of ginseng and eucalypt or their extracts, and drinking them promotes metabolism. However, this composition has been reported to have a drawback that the incorporation of ginseng causes poor urine output.
【０００４】さらに、第４８回日本栄養・食糧学会で目
鳥らによりコラーゲン分解物と、杜仲葉とを含む低蛋白
質食品がラットの肉芽形成を促進する効果がある旨報告
されている。本報告によれば、低蛋白質食に杜仲葉と人
参を混合した飼料を４週与えたラットの一部に、４〜５
週の１週間蛋白質に代えて分解コラーゲンを与えたとこ
ろ、低蛋白質食を５週続けたラットよりも肉芽量が多
く、さらに組織中のヒドロキシプロリンの含量も多く、
高蛋白質食を続けたラットと同程度の肉芽形成促進能が
あることが報告されている。しかも、高蛋白質食を続け
たラットと比較して体重の増加は少なく、低蛋白質食を
続けたラットと同程度の体重増加しか示さなかった。し
かるに、これを人間の一般生活に当てはめた場合には、
コラーゲンと杜仲と人参を同時に摂取することにより、
良好に新陳代謝の促進が図れることが示唆される。Further, at the 48th Annual Meeting of the Japanese Society of Nutrition and Food Science, Metori et al. Reported that a low protein food containing collagen degradation products and Tonaka leaf has an effect of promoting granulation in rats. According to this report, 4-5 weeks were given to a part of rats fed a low protein diet mixed with Tonaka leaf and ginseng for 4 weeks.
When degraded collagen was given in place of protein for one week, the amount of granulation was higher than that of rats that continued on a low protein diet for 5 weeks, and the content of hydroxyproline in the tissue was higher,
It has been reported that it has the same ability to promote granulation formation as rats that have continued on a high protein diet. Moreover, the rats gained less weight compared to rats that continued on the high protein diet, and showed only the same weight gain as rats that continued on the low protein diet. However, when this is applied to the general human life,
By taking collagen, Tonaka and ginseng at the same time,
It is suggested that metabolism can be promoted well.
【０００５】[0005]
【発明が解決しようとする課題】しかしながら、上記組
成の新陳代謝促進剤を調製したところで、組織合成促進
は図れるものの、皮膚のターンオーバーは十分促進でき
ず、肌のハリの低下、小ジワ、くすみ等の問題は未だ解
決されず、さらなる改良が望まれている。本発明は、蛋
白質を通常の食生活以上に摂取する必要がなく、しかも
新陳代謝を促進し、特に皮膚のターンオーバーを促進す
る皮膚賦活食品を開発することを目的とする。However, when a metabolism promoter having the above composition is prepared, tissue synthesis can be promoted, but skin turnover cannot be sufficiently promoted, resulting in reduction of skin firmness, fine wrinkles, dullness, etc. The problem has not been solved yet, and further improvement is desired. The present invention does not require protein to be consumed more than in a normal diet, and furthermore, promotes metabolism, and particularly promotes skin turnover.
An object of the present invention is to develop a skin activation food that.
【０００６】[0006]
【課題を解決するための手段】前記目的を解決するため
に本発明者らが鋭意検討を重ねた結果、杜仲と人参とコ
ラーゲンを必須成分とし、デオキシリボ核酸等の選択成
分を含有する皮膚賦活剤を用いることにより、該成分が
皮膚の新陳代謝を促進し、組織合成能が高まり、皮膚の
ターンオーバーを促進し、皮膚賦活剤として有効に機能
することを見出し本発明の完成に至った。すなわち、本
発明の皮膚賦活食品は、杜仲若しくはその抽出物と、人
参若しくはその抽出物と、コラーゲン若しくはその加水
分解物とを必須成分とし、これにデオキシリボ核酸、コ
ンドロイチン硫酸、ハトムギエキスの一種又は二種以上
を選択して配合することを特徴とする。 Means for Solving the Problems] As a result of the present inventors to solve the above object is intensive studies, Eucommia and carrot and co
By using a skin activator containing lagen as an essential component and a selective component such as deoxyribonucleic acid, the component promotes skin metabolism, increases tissue synthesis ability, promotes skin turnover, and enhances the skin activator. Have been found to function effectively, and the present invention has been completed. That is, the skin-activating food of the present invention is composed of tochu or its extract, carrot or its extract , collagen or its hydrolyzate.
A degraded product is an essential component, and one or more of deoxyribonucleic acid, chondroitin sulfate , and barley extract are selected and blended .
【０００７】[0007]
【発明の実施の形態】以下、本発明の実施形態をさらに
詳細に説明する。本発明は必須成分として、杜仲及び人
参若しくはこれらの抽出物及びコラーゲン若しくはその
加水分解物を含む。本発明に用いられる杜仲は、杜仲の
葉をそのまま若しくは杜仲エキスを抽出した抽出物とし
て用いる。DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, embodiments of the present invention will be described in more detail. The present invention provides, as essential components, eucommia and ginseng or their extracts and collagen or
Contains hydrolysates . Tochu used in the present invention uses Tochu leaves as they are or as an extract obtained by extracting a Tochu extract.
【０００８】すなわち、杜仲の葉をそのまま用いる場合
には、細かく裁断したものをそのまま、若しくはそれを
乾燥させる、若しくは前記粉砕した杜仲の葉を常法に従
い、例えば８０〜１２０℃で０．５〜２時間焙煎して得
たものを用いることが可能である。また、杜仲抽出物と
して用いる場合には、杜仲の葉をそのまま若しくはその
乾燥物を常法に従い、例えば水あるいは水性有機溶剤に
て、室温あるいは８０〜１００℃にて抽出して得られた
抽出液を濾過後、そのまま、若しくは必要に応じて濃縮
し、若しくは乾燥して粉末として用いることが可能であ
る。また、必要に応じては、発酵処理を行った後、焙
煎、濾過、濃縮等を経て得ることも可能である。[0008] That is, in the case of using Tonaka leaves as they are, they are cut into small pieces as they are, or are dried, or the above-mentioned ground Tonaka leaves are subjected to conventional methods, for example, at 80 to 120 ° C for 0.5 to 0.5 ° C. It is possible to use what was obtained by roasting for 2 hours. When used as a Tonaka extract, an extract obtained by extracting Tonaka leaves as it is or a dried product thereof in a conventional manner, for example, with water or an aqueous organic solvent at room temperature or at 80 to 100 ° C. Can be used as a powder after filtration, as it is, or if necessary, concentrated or dried. Further, if necessary, after fermentation treatment, it can be obtained through roasting, filtration, concentration and the like.
【０００９】また、本発明に用いられる人参は、朝鮮人
参をそのまま若しくは人参エキスを抽出した抽出物とし
て用いる。朝鮮人参は上記杜仲と同様に処理し、本発明
に用いることが可能である。さらに本発明は、コラーゲ
ン若しくはその加水分解物を必須成分として配合する。
上記必須成分に加えて、選択成分としてデオキシリボ核
酸、コンドロイチン硫酸、ハトムギエキスの一種若しく
は二種以上を選択して配合する。デオキシリボ核酸は、
サケ、イワシ、フグ、サバ等の白子に、コンドロイチン
硫酸はフカヒレ等に多量に含まれている。なお本発明
は、上記必須成分に加えて選択成分の一種または二種以
上を配合することにより本発明の特徴的効果を初めて発
揮することができるのである。The ginseng used in the present invention may be ginseng as it is or as an extract obtained by extracting a ginseng extract. Ginseng can be processed in the same manner as in the above-mentioned Tochu, and used in the present invention. Furthermore, the present invention is, collagen
Or a hydrolyzate thereof as an essential component.
In addition to the above essential components, one or more of deoxyribonucleic acid, chondroitin sulfate , and barley extract are selected and blended as optional components. Deoxyribonucleic acid is
Chondroitin sulfate is contained in large quantities in shark fins and the like in milt such as salmon, sardine, puffer fish and mackerel. In the present invention, the characteristic effects of the present invention can be exhibited for the first time by blending one or more selected components in addition to the above essential components.
【００１０】本発明の皮膚賦活食品を用いる場合には、
通常摂取者が一日に杜仲若しくはその抽出物（以下、杜
仲という）０．０２〜３ｇ／ｋｇ、人参若しくはその抽
出物（以下、人参という）０．００５〜１．５ｇ／ｋｇ
とすることが好ましい。杜仲０．０２ｇ未満、人参０．
００５ｇ未満では、本発明の目的とする効果を得ること
ができず、一方、杜仲３ｇ、人参１．５ｇ以上としても
それ以上の効果を望めない。また、本発明の皮膚賦活食
品中の選択成分の総配合量は、必須成分である杜仲及び
人参の総量に対して、２：１〜１：１の範囲で配合する
ことが好ましい。When using the skin- activating food of the present invention,
Usually, the daily intake is 0.02 to 3 g / kg of Tochu or its extract (hereinafter, referred to as Tonaka), ginseng or its extract (hereinafter, referred to as Ginseng) 0.005 to 1.5 g / kg per day
It is preferable that Tonaka less than 0.02g, ginseng 0.
If the amount is less than 005 g, the desired effects of the present invention cannot be obtained. On the other hand, even if the amount is 3 g or more and the ginseng is 1.5 g or more, no further effects can be expected. The total amount of the selected components in the skin- activating food of the present invention is preferably in the range of 2: 1 to 1: 1 with respect to the total amount of the essential components, Tochu and Ginseng.
【００１１】本発明の皮膚賦活食品は、菓子や清涼飲料
水や主食等の食品等種々の使用形態をとることができ、
食品に配合することにより皮膚賦活食品とすることが可
能である。さらに、本発明の皮膚賦活食品には上記必須
成分、選択成分の他、蛋白質、ローヤルゼリー、ムコ多
糖類などの動物性抽出物、ビタミン類、不飽和脂肪酸、
等の従来公知の皮膚賦活食品を配合することも可能であ
る。さらに、本発明の効果を損なわない範囲で、必要に
応じて食品に用いられる賦形剤、増量剤、甘味剤、香味
剤、着色剤等の添加剤を配合することも可能である。The skin-activating food of the present invention can take various forms of use such as foods such as confectionery , soft drinks and staple foods.
It can be made into a skin-activating food by being mixed with food. Further, the skin-activating food of the present invention, in addition to the above essential components, optional components, proteins, royal jelly, animal extracts such as mucopolysaccharides, vitamins, unsaturated fatty acids,
It is also possible to mix conventionally known skin activating foods such as. Further, as long as the effects of the present invention are not impaired, additives such as excipients, extenders, sweeteners, flavoring agents, coloring agents and the like used in foods can be added as needed.
【００１２】組織合成能の回復 本発明者は本発明のラット肉芽形成に及ぼす影響につい
て検討した。まず、ホルマリン濾紙法（ＦＦＰ法：A.Ta
naka et al, Endocrinol.Japan.1960(4),357〜364）に
より評価を行った。まず、実験方法について説明する。
本実験は、Ｒａｏらの報告（Rao et al, Leather Scien
ce, Vol.33(1),1986,1〜7）をもとに、長期間低蛋白質
食で飼育することによって新陳代謝を大きく低下させた
ラットにおける組織合成能の回復に対する本発明の影響
を検討したものである。 Restoration of Tissue Synthesis Ability The present inventors examined the effect of the present invention on rat granulation. First, formalin filter paper method (FFP method: A.Ta
naka et al, Endocrinol. Japan. 1960 (4), 357-364). First, an experimental method will be described.
This experiment was reported by Rao et al. (Rao et al, Leather Scien
ce, Vol. 33 (1), 1986, 1-7) to investigate the effect of the present invention on the restoration of tissue synthesis ability in rats whose metabolism has been significantly reduced by long-term low protein diet rearing. It was done.
【００１３】（１）実験動物 ６週齢のＷｉｓｔｅｒ系雄ラット２０匹を、一週間の予
備飼育後、４群に分け一群５匹とした。 （２）飼料 各群に表１に示す飼料及び飲料水を自由に与えた。(1) Experimental animals Twenty 6-week-old Wister male rats were divided into four groups after pre-breeding for one week, and each group was divided into five groups. (2) Feed The feed and drinking water shown in Table 1 were freely given to each group.
【表１】 ──────────────────────────────────── １群 ２群 ３群 ４群 ──────────────────────────────────── ６％蛋白質含有実験食 100.0% 98.7% 98.7% 98.7% 調整食ａ − 1.3% − − 調整食ｂ − − 1.3% − 調整食ｃ − − − 1.3% ──────────────────────────────────── 各調整食１．３％の組成を以下に示す。なお、配合量は
ｍｇで示す。また、６％蛋白質含有実験食の組成は後述
する。[Table 1] １ 1 group 2 groups 3 groups 4 groups ──実 験 Experimental diet containing 6% protein 100.0% 98.7% 98.7% 98.7% Adjusted diet a-1.3%--Adjusted meal b--1.3%-Adjusted meal c---1.3% ────────────────────────────組成 The composition of 1.3% for each prepared meal is shown below. The amount is shown in mg. The composition of the experimental diet containing 6% protein will be described later.
【００１４】[0014]
【表２】 ──────────────────────────────────── 調整食ａ 調整食ｂ 調整食ｃ ──────────────────────────────────── 杜仲・人参エキス ４３０ ４３０ − コラーゲン ２２０ − ２２０ サケ白子抽出物 １１０ − １１０ フカヒレエキス ９０ − ９０ ハトムギエキス ５０ − ５０ 部分α化澱粉 − ４７０ ４３０ ────────────────────────────────────[Table 2] ──────────────────────────────────── Adjusted meal a Adjusted meal b Adjusted meal c ─ ─────────────────────────────────── Tochu / Ginseng Extract 430 430-Collagen 220-220 Salmon Mushroom Extract 110-110 Shark fin extract 90-90 Adlay extract 50-50 Partially pregelatinized starch-470 430 ──────
【００１５】なお、ハトムギエキス５０ｍｇには原生薬
換算で１０００ｍｇのハトムギに相当し、サケ白子抽出
物には、１００ｍｇのデオキシリボ核酸、フカヒレエキ
スには、３０ｍｇのコンドロイチン硫酸が含有される。
また、杜仲・人参エキスは、以下の方法で得ることが可
能である。すなわち、杜仲葉及び人参をそれぞれ１０倍
量の水で熱時抽出する。これを濾過後、それぞれを乾燥
し粉末とした。杜仲エキス及び人参エキスを杜仲：人参
＝３：１となるように混合し、かつこの混合エキスを４
３０ｍｇが杜仲葉１．５ｇ、人参０．５ｇに相当するよ
う調製することにより得た。したがって、杜仲・人参エ
キスには、１．５ｇ相当の杜仲葉と、０．５ｇ相当の人
参が含まれている。It should be noted that 50 mg of barley extract corresponds to 1000 mg of barley in terms of a crude drug, salmon milt extract contains 100 mg of deoxyribonucleic acid, and shark fin extract contains 30 mg of chondroitin sulfate.
In addition, the Tonaka / Ginseng extract can be obtained by the following method. That is, the hot spring extract and the carrot are each extracted with 10 times the amount of water when hot. After filtration, each was dried to obtain a powder. The eucommia extract and the ginseng extract are mixed so that eucommia: ginseng = 3: 1, and this mixed extract is mixed with 4
It was obtained by preparing 30 mg to be equivalent to 1.5 g of Tonaka leaf and 0.5 g of carrot. Therefore, the Tonaka / Ginseng extract contains 1.5 g of Tonaka leaves and 0.5 g of ginseng.
【００１６】（３）評価 ［ＦＦＰ法］実験開始日より３週間目にエーテル麻酔の
下、７％ホルマリンを２０μｌ染み込ませた直径６ｍ
ｍ、重量８ｍｇの濾紙（TOYO No.126）をラット背部皮
下の４カ所に埋め込んだ。同日より所定の飼料、飲料水
でさらに１週間飼育後、エーテル麻酔下、心臓より採血
して屠殺した。(3) Evaluation [FFP method] Three weeks after the start of the experiment, 20 μl of 7% formalin was impregnated with ether under anesthesia for 6 m in diameter.
A filter paper (TOYO No.126) having a weight of 8 mg and a weight of 8 mg was embedded in four places under the back of the rat. On the same day, the animals were bred for an additional week with the prescribed feed and drinking water, and then were collected from the heart under ether anesthesia and sacrificed.
【００１７】上記飼料を用いて実験を行った結果を表３
に示す。なお、＊はStudent's t-test（有意水準p<0.0
5）により統計処理を行った場合に有意差が認められる
ものを示す。Table 3 shows the results of experiments using the above feed.
Shown in * Indicates Student's t-test (significance level p <0.0
The ones with a significant difference when statistical processing is performed according to 5) are shown.
【表３】 ──────────────────────────────────── １群 ２群 ３群 ４群 ──────────────────────────────────── 体重増(g) 71± 7 62± 7 49± 6 76± 5 肉芽湿重量(mg) 152±10 205±14* 189± 7* 152± 7 ────────────────────────────────────[Table 3] ──────────────────────────────────── 1 group 2 groups 3 groups 4 groups ──増 Weight gain (g) 71 ± 7 62 ± 7 49 ± 6 76 ± 5 Granulation wet weight (mg) 152 ± 10 205 ± 14 * 189 ± 7 * 152 ± 7 ───────────────────────────── ───────
【００１８】選択成分であるデオキシリボ核酸等のみを
配合した４群では、１群と比較して体重増加及び肉芽組
織合成とも差はなかった。また、実験食に本発明を配合
した２群及び実験食に杜仲・人参を配合した３群では、
体重増加は１群と同程度であった。しかしながら、両群
とも肉芽湿重量において、コントロールとなる１群に対
して有意差が認められ、本発明を配合した２群において
顕著な増加を示した。したがって、杜仲−人参を加える
ことにより肉芽組織合成能が高くなり、さらに、デオキ
シリボ核酸等の選択成分を同時に加えて与えることによ
り、組織合成能の回復をはかることが可能であり、新陳
代謝が促進されることが示唆される。In the four groups containing only the selected component such as deoxyribonucleic acid, there was no difference in weight gain and granulation tissue synthesis as compared with the one group. In addition, in the two groups in which the present invention was added to the experimental food and the three groups in which the experimental food was added with Tonaka and ginseng,
Weight gain was similar to group 1. However, in both groups, a significant difference was observed in the granulation wet weight from the control group, and the two groups to which the present invention was added showed a remarkable increase. Therefore, the addition of Tochu-Ginseng increases the ability of synthesizing granulation tissue, and the simultaneous addition and selection of a selected component such as deoxyribonucleic acid makes it possible to restore the ability of synthesizing tissue, thereby promoting metabolism. It is suggested that
【００１９】皮膚のターンオーバーの回復 次に、ダンシルクロライド法による皮膚のターンオーバ
ーの検討を行った。 （１）実験動物 ６週齢のＷｉｓｔａｒ系雄ラット２０匹を１週間の予備
飼育後、４群に分け１群５匹とした。なお、各群の動物
はダンシルクロライド塗布３日前より１匹飼いとした。 Recovery of skin turnover Next, skin turnover by the dansyl chloride method was examined. (1) Experimental animals Twenty six-week-old Wistar male rats were preliminarily reared for one week and divided into four groups, each group comprising five rats. One animal in each group was kept 3 days before the application of dansyl chloride.
【００２０】（２）飼料 各群に表４に示す飼料及び飲料水は自由に与えた。(2) Feed The feed and drinking water shown in Table 4 were freely given to each group.
【表４】 ──────────────────────────────────── １群 ２群 ３群 ４群 ──────────────────────────────────── １１％蛋白質含有実験食 100.0% 97.0% 97.0% 97.0% 調整食ａ − 3.0% − − 調整食ｂ − − 3.0% − 調整食ｃ − − − 3.0% ──────────────────────────────────── 各調整食は、表２に示す物を用いた。なお、１１％蛋白
質含有実験食については後述する。[Table 4] ──────────────────────────────────── 1 group 2 groups 3 groups 4 groups ──実 験 Experimental diet containing 11% protein 100.0% 97.0% 97.0% 97.0% Adjusted diet a-3.0%--Adjusted meal b--3.0%-Adjusted meal c---3.0% ────────────────────────────調整 The prepared foods shown in Table 2 were used. The experimental diet containing 11% protein will be described later.
【００２１】（３）評価 各動物につき、体重、各臓器の重量及び、ダンシルクロ
ライド法による皮膚の蛍光消失日を測定した。 ［体重及び各臓器の重量の測定］実験開始日より６週間
目にエーテル麻酔下で、心臓より採血し屠殺した。 ［ダンシルクロライド法の蛍光消失日の測定］実験開始
日より各群の動物に飼料及び飲料水を自由に与えた。実
験開始日より４週間目に、エーテル麻酔下、ラットの背
部を剃毛し、２％ダンシルクロライド／ＥｔＯＨ溶液５
μｌをラット背部（ラット自身でふれることができない
部分）に塗布した。塗布後、２４時間目より蛍光強度を
測定し、蛍光の５０％消失日を算定した。なお、各統計
処理は、Duncan Multipl testを用いて有意水準をp<0.0
5として対照群（１群）と比較解析した。(3) Evaluation For each animal, the body weight, the weight of each organ, and the date of the disappearance of the skin fluorescence by the dansyl chloride method were measured. [Measurement of body weight and weight of each organ] Six weeks after the start of the experiment, blood was collected from the heart and killed under ether anesthesia. [Measurement of Date of Fluorescence Dissipation by Dansyl Chloride Method] From the start of the experiment, animals in each group were fed food and drinking water freely. Four weeks after the start of the experiment, the back of the rat was shaved under ether anesthesia, and 2% dansyl chloride / EtOH solution 5
μl was applied to the back of the rat (the area where the rat cannot touch itself). The fluorescence intensity was measured 24 hours after application, and the 50% disappearance date of the fluorescence was calculated. For each statistical processing, the significance level was determined using the Duncan Multipl test as p <0.0
Comparative analysis was performed as 5 with the control group (1 group).
【００２２】まず、各群の体重変化を表５に示す。First, the change in body weight of each group is shown in Table 5.
【表５】 ──────────────────────────────────── 開始日の体重Ａ（ｇ） 最終日の体重Ｂ（ｇ） Ｂ−Ａ（ｇ） ──────────────────────────────────── １群 250 ± 3 388 ± 7 138 ± 6 ２群 249 ± 4 378 ± 6 129 ± 3 ３群 246 ± 4 368 ± 7 122 ± 7 ４群 249 ± 6 387 ± 15 138 ± 10 ──────────────────────────────────── この１群と比較して、杜仲−人参及び／またはデオキシ
リボ核酸等を与えた２〜４群はそれぞれ、１２９ｇ、１
２２ｇ、１３８ｇであり、１群との間に有意差は認めら
れなかった。[Table 5] 体重 Starting weight A (g) Last day Weight B (g) BA (g) ──────────────────────────────────── 1 group 250 ± 3 388 ± 7 138 ± 6 2nd group 249 ± 4 378 ± 6 129 ± 3 3rd group 246 ± 4 368 ± 7 122 ± 7 4th group 249 ± 6 387 ± 15 138 ± 10 ────────杜 Compared to this one group, two to which the eucommia-ginseng and / or deoxyribonucleic acid etc. were given The four groups each had 129 g, 1
22 g and 138 g, and no significant difference from one group was observed.
【００２３】次に、各群の各臓器の体重に対する割合を
表６に示す。Next, Table 6 shows the ratio of each organ to the weight of each organ in each group.
【表６】 ──────────────────────────────────── 肝臓 腎臓 脾臓 心臓 胸腺 (×102) (×103) (×103) (×103) (×103 ) ──────────────────────────────────── １群 2.85±0.09 5.60±0.20 1.75±0.08 2.65±0.04 1.45±0.10 ２群 2.70±0.06 5.61±0.07 1.67±0.05 2.62±0.03 1.40±0.10 ３群 2.74±0.03 5.62±0.16 1.73±0.08 2.69±0.04 1.38±0.04 ４群 2.74±0.11 5.75±0.27 1.63±0.06 2.70±0.06 1.38±0.06 ──────────────────────────────────── 上記結果より明らかなように、２〜４群の各種臓器の比
体重値には対照群である１群と比較して、全ての臓器に
おいて有意差は認められず、解剖時の肉眼所見によって
も変化は認められなかった。したがって、体重の変化と
各臓器の比体重値を鑑みると、本発明の効果は、ラット
の成長や各種臓器には影響を及ぼさないことが示唆され
る。[Table 6] ──────────────────────────────────── Liver Kidney Spleen Heart Thymus (× 10 2 ) (× 10 3 ) (× 10 3 ) (× 10 3 ) (× 10 3 ) ──────────────────────────────群 Group 1.85 ± 0.09 5.60 ± 0.20 1.75 ± 0.08 2.65 ± 0.04 1.45 ± 0.10 Group 2 2.70 ± 0.06 5.61 ± 0.07 1.67 ± 0.05 2.62 ± 0.03 1.40 ± 0.10 Group 3 2.74 ± 0.03 5.62 ± 0.16 1.73 ± 0.08 2.69 ± 0.04 1.38 ± 0.04 4 groups 2.74 ± 0.11 5.75 ± 0.27 1.63 ± 0.06 2.70 ± 0.06 1.38 ± 0.06 ──────────────────────────よ う As is evident from the above results, the specific body weight values of various organs in groups 2 to 4 were significantly different in all organs compared to group 1 as a control group. No changes were noted by gross findings at autopsy. Therefore, in view of the change in body weight and the specific body weight of each organ, it is suggested that the effect of the present invention does not affect the growth of rats and various organs.
【００２４】次に、各群のダンシルクロライド法による
蛍光消失日の結果を表７に示す。Next, the results of the fluorescence extinction days of each group by the dansyl chloride method are shown in Table 7.
【表７】 ──────────────────────────────────── 蛍光の５０％消失日 ──────────────────────────────────── １群 4.73 ±0.41 ２群 3.66 ±0.01* ３群 5.13 ±0.66 ４群 3.95 ±0.41 ──────────────────────────────────── 以上の結果より明らかなように皮膚ターンオーバーに関
しては、蛍光強度の５０％消失日が２群の４．７３日と
比較して、杜仲−人参エキス若しくはデオキシリボ核酸
等を加えた３群及び４群は、蛍光強度の５０％消失日が
５．１３日、３．９５日であり、２群と比較して有意差
は認められない。[Table 7] 日 Day of 50% disappearance of fluorescence ────群 Group 1 4.73 ± 0.41 Group 2 3.66 ± 0.01 * Group 3 5.13 ± 0.66 Group 4 3.95 ± 0.41 皮膚 Skin turnover as evident from the above results As for the 3rd and 4th groups to which the Tonaka-carrot extract or deoxyribonucleic acid, etc. were added, the 50% disappearance date of the fluorescence intensity was 5% compared to 4.73 days of the 2 groups where the 50% disappearance date of the fluorescence intensity was 5 days. .13 days, 3.95 days, and no significant difference was observed in comparison with the two groups.
【００２５】一方、本発明である杜仲−人参エキスとデ
オキシリボ核酸等を加えて与えた２群では、蛍光強度の
５０％消失日が３．６６日と、２群と比べ有意に消失速
度が速く、新陳代謝が活発化され、しかもターンオーバ
ー期間が短くなっていることが示唆される。したがっ
て、本発明を人間に適用した場合、新陳代謝を促進し、
特に皮膚のターンオーバーを促進することが可能であ
り、老化に伴う新陳代謝の低下、特に皮膚のターンオー
バーの促進が図られ、若々しい肌を得ることができるこ
とが示唆される。On the other hand, in the two groups to which the Tonaka-carrot extract and deoxyribonucleic acid etc. of the present invention were added, the 50% disappearance day of the fluorescence intensity was 3.66 days, which is significantly faster than the two groups. It is suggested that the metabolism is activated and the turnover period is shortened. Therefore, when the present invention is applied to humans, it promotes metabolism,
In particular, it is possible to promote skin turnover, and it is suggested that metabolism is reduced with aging, especially skin turnover is promoted, and that youthful skin can be obtained.
【００２６】飼料の説明 上記検討で用いた６％蛋白質含有実験食及び１１％蛋白
質含有実験食の組成を表７に示す。 Description of the Feed Table 7 shows the compositions of the experimental food containing 6% protein and the experimental food containing 11% protein used in the above examination.
【表７】 ──────────────────────────────────── ６％実験食 １１％実験食 ──────────────────────────────────── ミルクカゼイン ７．０％ １３．０％ コーンスターチ ６３．０ ５７．０ グラニュー糖 １０．０ １０．０ コーンオイル ６．０ ６．０ アビセルセルロース ３．０ ３．０ ＫＣフロック ２．０ ２．０ オカノール（α化澱粉） １．０ １．０ 混合ビタミン １．０ １．０ 混合ミネラル ７．０ ７．０ ────────────────────────────────────[Table 7] ６ 6% experimental diet 11% experimental diet ──ミ ル ク Milk casein 7.0% 13.0% Corn starch 63.0 57. 0 Granulated sugar 10.0 10.0 Corn oil 6.0 6.0 Avicel cellulose 3.0 3.0 KC floc 2.0 2.0 Okanol (gelatinized starch) 1.0 1.0 Mixed vitamin 1.0 1.0 Mixed minerals 7.0 7.0
【００２７】なお、上記表７の混合ビタミン及び混合ミ
ネラルはそれぞれ表７及び表８に記載の組成の混合物で
あり、単位はｍｇである。The mixed vitamins and minerals shown in Table 7 are mixtures having the compositions shown in Tables 7 and 8, respectively, and the unit is mg.
【表８】 ──────────────────────────────────── 混合ビタミン ──────────────────────────────────── ビタミンＡ・Ｄ3（５０万IU/１０万IU） ２．４ ｍｇ Ｅ（５０％） ２０．０ Ｋ3 ０．４ Ｂ1 １．５ Ｂ2 １．５６ Ｂ6 １．０２ Ｂ12（０．１％） ５．０ ビオチン（２．０％） ０．５ ＤＬ−パントテン酸Ｃａ ４．０ ＰＡＢＡ １０．１５ ニコチン酸 １０．１５ イノシトール １５．０ 葉酸 ０．２ 塩化コリン ３００．０ コーンスターチ ６２８．１２ ──────────────────────────────────── 合 計 １０００．０ ｍｇ ────────────────────────────────────[Table 8] ──────────────────────────────────── Mixed vitamins ──────── ──────────────────────────── Vitamin A ・ D 3 (500,000 IU / 100,000 IU) 2.4 mg E (50% ) 20.0 K 3 0.4 B 1 1.5 B 2 1.56 B 6 1.02 B 12 (0.1%) 5.0 biotin (2.0%) 0.5 DL- pantothenic acid Ca 4.0 PABA 10.15 Nicotinic acid 10.15 Inositol 15.0 Folic acid 0.2 Choline chloride 300.0 Corn starch 628.12 ─────────────── Total 1000.0 mg ───────────────────────────── ───────
【００２８】[0028]
【表９】 ──────────────────────────────────── 混合ミネラル ──────────────────────────────────── ＣａＣＯ3 １３５５．４ ｍｇ ＫＨ3ＰＯ4 １７３０．０ ＣａＨＰＯ4・２Ｈ2Ｏ １５００．０ ＭｇＳＯ4・７Ｈ2Ｏ ８００．０ ＮａＣｌ ６００．０ ＦｅＣ6Ｃ5Ｏ7・５Ｈ2Ｏ １９０．０ ５ＺｎＯ・２ＣＯ2・４Ｈ2Ｏ ６．０ ＣｕＳＯ4・５Ｈ2Ｏ １．２６ ＣｏＣＬ2・６Ｈ2Ｏ ０．４ Ｃａ（ＩＯ3）2 １．５４ ＭｎＳＯ4・４Ｈ2Ｏ １５．４ コーンスターチ ８００．０ ──────────────────────────────────── 合 計 ７０００．０ ｍｇ ────────────────────────────────────[Table 9] ──────────────────────────────────── Mixed minerals ──────── ──────────────────────────── CaCO 3 1355.4 mg KH 3 PO 4 1730.0 CaHPO 4 · 2H 2 O 1500.0 MgSO 4 · 7H 2 O 800.0 NaCl 600.0 FeC 6 C 5 O 7 · 5H 2 O 190.0 5ZnO · 2CO 2 · 4H 2 O 6.0 CuSO 4 · 5H 2 O 1.26 CoCL 2 · 6H 2 O 0.4 Ca (IO 3) 2 1.54 MnSO 4 · 4H 2 O 15.4 cornstarch 800.0 ─────────────────────── ７００ Total 7000.0 mg ─────────────────────────────── ────
【００２９】[0029]
【発明の効果】本発明の皮膚賦活食品は、新陳代謝を促
進し、特に皮膚のターンオーバーを促進することが可能
であるという優れた効果を発揮するものである。 The skin- activating food of the present invention has an excellent effect of promoting metabolism and, in particular, of promoting skin turnover.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 ＦＩ Ａ６１Ｋ 38/00 Ａ６１Ｐ 17/00 38/17 43/00 １０７ Ａ６１Ｐ 17/00 Ａ６１Ｋ 37/12 43/00 １０７ 37/18 (56)参考文献 特開 平７−278012（ＪＰ，Ａ) 特開 平６−92821（ＪＰ，Ａ) 特開 昭61−56114（ＪＰ，Ａ) 特開 平５−170640（ＪＰ，Ａ) 特開 平２−96509（ＪＰ，Ａ) 特開 昭63−139104（ＪＰ，Ａ) 特開 平６−256139（ＪＰ，Ａ) 特開 昭62−96404（ＪＰ，Ａ) 特開 平６−336418（ＪＰ，Ａ) 特開 昭60−214721（ＪＰ，Ａ) (58)調査した分野(Int.Cl.7，ＤＢ名) A61K 35/78 A23L 1/30 A61K 31/70 A61K 31/726 A61K 35/60 A61K 38/00 A61K 38/17 ＢＥＩＬＳＴＥＩＮ（ＳＴＮ) ＣＡ（ＳＴＮ) ＭＥＤＬＩＮＥ（ＳＴＮ)──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI A61K 38/00 A61P 17/00 38/17 43/00 107 A61P 17/00 A61K 37/12 43/00 107 37/18 (56 References JP-A-7-278012 (JP, A) JP-A-6-92821 (JP, A) JP-A-61-56114 (JP, A) JP-A-5-170640 (JP, A) JP-A-2-96509 (JP, A) JP-A-63-139104 (JP, A) JP-A-6-256139 (JP, A) JP-A-62-96404 (JP, A) JP-A-6-336418 (JP, A A) JP-A-60-214721 (JP, A) (58) Fields investigated (Int. Cl. 7 , DB name) A61K 35/78 A23L 1/30 A61K 31/70 A61K 31/726 A61K 35/60 A61K 38/00 A61K 38/17 BEILSTEIN (STN) CA (STN) MEDLINE (STN)
Claims (1)
はその抽出物と、コラーゲン若しくはその加水分解物と
を必須成分とし、これにデオキシリボ核酸、コンドロイ
チン硫酸、ハトムギエキスの一種又は二種以上を選択し
て配合することを特徴とする皮膚賦活食品。And 1. A Eucommia or extracts thereof, and the ginseng or its extracts, collagen or essential components and a hydrolyzate which the deoxyribonucleic acid, chondroitin sulfate, and select one or two or more of c Tomugiekisu A skin-activating food characterized by being blended together.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24863195A JP3308433B2 (en) | 1995-08-31 | 1995-08-31 | Skin activating food |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24863195A JP3308433B2 (en) | 1995-08-31 | 1995-08-31 | Skin activating food |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0967262A JPH0967262A (en) | 1997-03-11 |
| JP3308433B2 true JP3308433B2 (en) | 2002-07-29 |
Family
ID=17180991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP24863195A Expired - Lifetime JP3308433B2 (en) | 1995-08-31 | 1995-08-31 | Skin activating food |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3308433B2 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010075842A (en) * | 2000-01-20 | 2001-08-11 | 김미혜 | Functional food |
| JP2002275078A (en) * | 2001-01-11 | 2002-09-25 | Kanebo Ltd | Lipolysis promoter |
| JP2004035456A (en) * | 2002-07-03 | 2004-02-05 | Pola Chem Ind Inc | Promoter for keratinocyte maturation and oral administration composition containing the same |
| JP5635221B2 (en) * | 2004-12-24 | 2014-12-03 | 株式会社明治 | Fermented milk for skin improvement and / or treatment and method for producing the same |
| JP5722282B2 (en) * | 2004-12-24 | 2015-05-20 | 株式会社明治 | Skin improving agent and skin improving method |
| JP4982718B2 (en) * | 2005-08-31 | 2012-07-25 | 株式会社林原 | Composition for oral intake for beautiful skin |
| JP5689222B2 (en) | 2006-11-15 | 2015-03-25 | 株式会社明治 | Collagen peptide composition and food and drink containing the same |
| EP2095820A4 (en) * | 2006-12-26 | 2012-01-11 | Meiji Dairies Corp | Fermented milk for improving and/or treating skin and method for producing the same |
| JP5312780B2 (en) * | 2007-12-19 | 2013-10-09 | 国立大学法人鳥取大学 | Food / drink and pharmaceutical composition for reducing blood ammonia concentration |
| CA2759424C (en) | 2009-04-28 | 2018-01-02 | Meiji Co., Ltd. | Collagen peptide composition having good ability to enter the blood and food or beverage containing the same |
| JP6042696B2 (en) * | 2011-10-31 | 2016-12-14 | 興和株式会社 | Anti-containing composition |
| JP2014214141A (en) * | 2013-04-30 | 2014-11-17 | 興和株式会社 | Sinomenium stem-containing composition |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60214721A (en) * | 1984-04-06 | 1985-10-28 | Inahata Koryo Kk | Cosmetic composition for preventing liver-spot |
| JPS6156114A (en) * | 1984-08-27 | 1986-03-20 | Kanebo Ltd | Cosmetic for preventing skin aging |
| JPH0615465B2 (en) * | 1985-10-21 | 1994-03-02 | 鐘紡株式会社 | Whitening cosmetics |
| JPS63139104A (en) * | 1986-11-28 | 1988-06-10 | Kanebo Ltd | Skin cosmetic |
| JP2553474B2 (en) * | 1988-09-29 | 1996-11-13 | 鐘紡株式会社 | Skin cosmetics |
| JPH05170640A (en) * | 1991-12-24 | 1993-07-09 | Kanebo Ltd | Skin medicine for external use |
| JP3349729B2 (en) * | 1992-09-14 | 2002-11-25 | 一丸ファルコス株式会社 | Tonaka leaf extract-containing skin cosmetics. |
| JP3115445B2 (en) * | 1993-03-01 | 2000-12-04 | 鐘紡株式会社 | Whitening cosmetics |
| JP3805798B2 (en) * | 1993-05-28 | 2006-08-09 | 株式会社コーセー | Cosmetics |
| JP3782122B2 (en) * | 1994-04-11 | 2006-06-07 | サンスター株式会社 | Metabolism promoter for oral intake and food containing the same |
-
1995
- 1995-08-31 JP JP24863195A patent/JP3308433B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0967262A (en) | 1997-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE68919114T2 (en) | Undenatured whey protein concentrate. | |
| JP3782122B2 (en) | Metabolism promoter for oral intake and food containing the same | |
| US8759405B2 (en) | Stevia extract or steviol for hair care | |
| JP3308433B2 (en) | Skin activating food | |
| JPS63502558A (en) | Sweet confectionery products and their manufacturing methods | |
| DE2741003A1 (en) | PEPTIDE MIXTURES OBTAINED FROM MATERIAL CONTAINING COLLAGEN OR GELATIN, METHOD FOR MANUFACTURING THEREOF AND USES | |
| JP2017086079A (en) | Material having functionality enhanced by utilizing maillard reaction, and food product/pet food using the same | |
| Shimeno et al. | Metabolic response to dietary lipid to protein ratios in common carp | |
| JP2000512154A (en) | How to enhance docosahexaenoic acid in milking dairy cows | |
| JP2553827B2 (en) | Rabbit bait | |
| EP1916913B1 (en) | Protein composition for treating a physiologically caused, clinically normal increased need for protein | |
| JP3146086B2 (en) | Chicken feed | |
| JPS60186261A (en) | Solid food composition | |
| KR101629517B1 (en) | Oral composition | |
| RU2202896C2 (en) | Feed for dogs and fur animals | |
| AU781989C (en) | Method for treating fur or hair pigmentation of domestic carnivores | |
| DE60209793T2 (en) | MODIFIED METHIONOLOGICAL NUTRITION AND METHOD FOR THE PRODUCTION THEREOF | |
| JP3248170B2 (en) | Food containing chondroitin sulfate protein complex | |
| JP2002540778A (en) | Flavor | |
| Rose | The amino acids in nutrition | |
| JPS63503036A (en) | food ingredients | |
| DE2226148A1 (en) | NEW FEED MIX | |
| JP2001002577A (en) | Lipid metabolism improver | |
| JPH10113131A (en) | Fish feed additive oil and fish feed for improving meat quality | |
| JP2002034469A (en) | Method for improving quality of flesh of cultured fish |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20020423 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090517 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090517 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100517 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110517 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120517 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130517 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140517 Year of fee payment: 12 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |